US5120712A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Insulinotropic hormone
Assignee: General Hospital Corp
•
Filing: 1990-06-01
•
Granted: 1992-06-09
•
Expires: 2010-06-01
Abstract
Abstract A fragment of glucagon-like peptide I (GLP-1) has been found to be an insulinotropic hormone. This insulinotropic hormone comprises amino acid residues 7-37 of GLP-1. The insulinotropic hormone is useful as a potential therapy for Diabetes Mellitus.
Inventors
- 👤 Joel Habener
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 14:00
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/575; C07K14/605; A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/22; A61K38/26
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
118 words
A molecule selected from the group consisting of: (a) a peptide having the amino acid sequence: ##STR2## and (b) a derivative of said peptide (a), wherein said derivative is selected from the group consisting of: (1) a pharmaceutically acceptable acid addition salt of said peptide; (2) a pharmaceutically acceptable carboxylate salt of said peptide; (3) a pharmaceutically acceptable lower alkyl ester of said peptide; and, (4) a pharmaceutically acceptable amide of said peptide wherein said pharmaceutically acceptable amide is selected from the group consisting of amide, lower alkyl amide and lower dialkyl amide; wherein said molecule is substantially free of natural contaminants, and has an insulinotropic activity which exceeds the insulinotropic activity of GLP-1 (1-36) or GLP-1 (1-37).
Claim 2
Dependent Claim
118 words
A molecule selected from the group consisting of: (a) a peptide having the amino acid sequence: ##STR2## and (b) a derivative of said peptide (a), wherein said derivative is selected from the group consisting of: (1) a pharmaceutically acceptable acid addition salt of said peptide; (2) a pharmaceutically acceptable carboxylate salt of said peptide; (3) a pharmaceutically acceptable lower alkyl ester of said peptide; and, (4) a pharmaceutically acceptable amide of said peptide wherein said pharmaceutically acceptable amide is selected from the group consisting of amide, lower alkyl amide and lower dialkyl amide; wherein said molecule is substantially free of natural contaminants, and has an insulinotropic activity which exceeds the insulinotropic activity of GLP-1 (1-36) or GLP-1 (1-37).
Claim 3
Dependent Claim
10 words
The molecule of claim 1 which is said peptide (a).
Claim 4
Dependent Claim
14 words
The molecule of claim 1 which is said derivative (b) of said peptide (a).
Claim 5
Dependent Claim
24 words
The molecule of claim 3, wherein said amide is selected from the group consisting of a lower alkyl amide and a lower dialykyl amide.
Claim 6
Dependent Claim
149 words
An insulintropic composition which comprises an insulinotropic molecule in an amount effective to stimulate insulin secretion in a patient for treatment of maturity onset diabetes mellitus, said molecule being selected from the group consisting of: (a) a peptide having the amino acid sequence: ##STR3## and (b) a derivative of said peptide (a), wherein said derivative is selected from the group consisting of: (1) a pharmaceutically acceptable acid addition salt of said peptide; (2) a pharmaceutically acceptable carboxylate salt of said peptide; (3) a pharmaceutically acceptable lower alkyl ester of said peptide; and, (4) a pharmaceutically acceptable amide of said peptide wherein said pharmaceutically acceptable amide is selected from the group consisting of amide, lower alkyl amide and lower dialkyl amide; wherein said molecule has an insulinotropic activity which exceeds the insulinotropic activity of GLP-1 (1-36) or GLP-1 (1-37); said molecule combined in admixture with a suitable pharmaceutically acceptable carrier.
Claim 7
Dependent Claim
149 words
An insulintropic composition which comprises an insulinotropic molecule in an amount effective to stimulate insulin secretion in a patient for treatment of maturity onset diabetes mellitus, said molecule being selected from the group consisting of: (a) a peptide having the amino acid sequence: ##STR3## and (b) a derivative of said peptide (a), wherein said derivative is selected from the group consisting of: (1) a pharmaceutically acceptable acid addition salt of said peptide; (2) a pharmaceutically acceptable carboxylate salt of said peptide; (3) a pharmaceutically acceptable lower alkyl ester of said peptide; and, (4) a pharmaceutically acceptable amide of said peptide wherein said pharmaceutically acceptable amide is selected from the group consisting of amide, lower alkyl amide and lower dialkyl amide; wherein said molecule has an insulinotropic activity which exceeds the insulinotropic activity of GLP-1 (1-36) or GLP-1 (1-37); said molecule combined in admixture with a suitable pharmaceutically acceptable carrier.
Claim 8
Dependent Claim
14 words
The insulinotropic composition of claim 5, wherein said insulinotropic molecule is said peptide (a).
Claim 9
Dependent Claim
18 words
The insulinotropic composition of claim 5, wherein said insulinotropic molecule is said derivative (b) of said peptide (a).
Claim 10
Independent Claim
145 words
A method for treating maturity onset diabetes mellitus in an individual in need of such treatment, wherein said method comprises providing an amount of an insulintropic molecule sufficient to treat said diabetes; wherein said molecule is selected from the group consisting of: (a) a peptide having the amino acid sequence: ##STR4## and (b) a derivative of said peptide (a), wherein said derivative is selected from the group consisting of: (1) a pharmaceutically acceptable acid addition salt of said peptide; (2) a pharmaceutically acceptable carboxylate salt of said peptide; (3) a pharmaceutically acceptable lower alkyl ester of said peptide; and, (4) a pharmaceutically acceptable amide of said peptide wherein said pharmaceutically acceptable amide is selected from the group consisting of amide, lower alkyl amide and lower dialkyl amide; wherein said molecule has an insulinotropic activity which exceeds the insulinotropic activity of GLP-1 (1-36) or GLP-1 (1-37).
Claim 11
Independent Claim
145 words
A method for treating maturity onset diabetes mellitus in an individual in need of such treatment, wherein said method comprises providing an amount of an insulintropic molecule sufficient to treat said diabetes; wherein said molecule is selected from the group consisting of: (a) a peptide having the amino acid sequence: ##STR4## and (b) a derivative of said peptide (a), wherein said derivative is selected from the group consisting of: (1) a pharmaceutically acceptable acid addition salt of said peptide; (2) a pharmaceutically acceptable carboxylate salt of said peptide; (3) a pharmaceutically acceptable lower alkyl ester of said peptide; and, (4) a pharmaceutically acceptable amide of said peptide wherein said pharmaceutically acceptable amide is selected from the group consisting of amide, lower alkyl amide and lower dialkyl amide; wherein said molecule has an insulinotropic activity which exceeds the insulinotropic activity of GLP-1 (1-36) or GLP-1 (1-37).
Claim 12
Dependent Claim
19 words
The method for treating maturity onset diabetes mellitus of claim 8, wherein said insulinotropic molecule is said peptide (a).
Claim 13
Dependent Claim
23 words
The method for treating maturity onset diabetes mellitus of claim 8, wherein said insulinotropic molecule is said derivative (b) of said peptide (a).
References Cited (Backward Citations)
EP0044168A1
Cited
EP0082731A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-06-09 | 1995-12-09 | 1996-06-09 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-06-09 | 1999-12-09 | 2000-06-09 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-06-09 | 2003-12-09 | 2004-06-09 | $7700.00 | Window Closed / Lapsed |